Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)Nizar M. Tannir, Oleg Karyakin, Walter Hong et al.|Journal of Clinical Oncology|2024Cited by 26
Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07)Erika Hamilton, Fabrice André, Komal Jhaveri et al.|Cancer Research|2023Cited by 5
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)Arlene O. Siefker‐Radtke, Yohann Loriot, Robert Huddart et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 0